Good Thank Jim. you Thank for joining us. you, evening.
each I want on expecting to details website During what drug XXXX to if more. them and the months. our my are share all I programs highlight we’ve slide, will briefly in the in study posted next be be time but you our with should development you XX accomplished not you over the slides what plan on today, covering
a Slide snapshot slide, This slide provides Processa first of with our you to X. go Let’s the highlights.
life need market includes treatment the have medical drug focused Processa potential of are greater on option. a improving you unmet of survival that medical $X have drug option blockbuster Processa each unmet As of our to treatment patients independent being or which five need addresses investors, Processa better a each who need size shots of This within giving with have either staff, These a is a billion. five goal who is and/or Each know, our development than company, opportunities the an or condition. drug. quality patients on no a for means our drugs pipeline different
answer regulatory clinical science FDA contracts, and scientific approach develop of number worked ago years the In way development we addition, to two we our XX not but started all blockbusters, we the have This only different best when drugs, developing we five going process that are a at simultaneously now FDA but are all potential all to through five questions. regulatory on determining is process. stages,
expect within achieve led now a at to from drug as I and have contracts development each these to end August near-term our drugs the FDA March to Our milestones milestones review of the number of year. discuss briefly of guidances. five our multiple the that we I’ll pipeline. We on
Slide the slide. Next point remind only in some five this describes on slide. already spoken I’ve of that pipeline. one drugs To criteria these the used our everyone, key item to to to like other slides, would Since X out select we have I
the drugs efficacy red that there in box The means of states very for five some of similar evidence, or drug for this each second a evidence clinical the is in efficacy with population targeted criteria the pharmacology.
five all the how that the they have companies, at of If of evidence $X you efficacy can population. in some and the pipeline potential say many targeted companies have drug look biotech billion in positive five other
slide. Next
should each are at XXXX we a of on XXX And be that next-generation point fourth presented Now expect for of in Instead going using XXXX, The the clinical drug three each I’d rebranding let’s slide. out XXXX, of pipeline. XXXXX. the key look slide, that our ready to summary in are these into of development, now like all development and we achieve which details have four clinical milestones drugs the the this year. of hit key we of status will for drug XXXX, drugs. the and XXXX In to the milestones by drug, end the we capecitabine,
will each achievements emphasizing five later provide for background and each be slides in drug. milestones XXXX XXXX on the the do Although information the drugs, value-added that of I some
Next slide.
have Let’s readout first should capecitabine, which next-generation some review data the mid-XXXX.
Next slide.
that is modifier used with in of of capecitabine, treatment X-FU. cancer designated to administered drugs chemotherapy prodrug XXXX, the and which cornerstone XXXX Next-generation one the chemotherapy at we chemotherapy capcitabine, previously Capecitabine form cepcitabine. a includes oral
the cells synthesized in demonstrated X-FU after to the administration, from next-generation DPD metabolized has side side FDA-approved DPD formed normal novo the side effect but can in is of kills dose shifting forms that XX they see to metabolite body, capecitabine metabolic cells in DPD dose shift, new the XX of the existing cause activity the a metabolite the greater XXXX, last As diagram This through over metabolize metabolism X-FU hours for know nucleotide, to can also the kills resulting down be DPD We looking which X-FU therapeutic And to the is irreversibly than being because de present, the being FBAL, like results present limiting. left time. inhibits into right effects with right does to called the of shutting can side, you line single XXXX these no is can however, of which capecitabine. forever FBAL. X-FU side not side FBAL. no XXXX inhibited capecitabine for and potency The shutdown XXXX effects, to X-FU, at XXx a if DPD neutrophils. cancer and side that the scheme XXXX
only capecitabine dosing. and to However, days to seven the potency last not increased hours XX last all for XX of appeared for did
Next slide.
capecitabine achieve to seven that understand XX% FBAL. XXXX capecitabine for the of DPD de need exposure XXXX. have the can exposure to while FBAL that novo of better X-FU determine than compared efficacy We to would still of capecitabine. profile of dosing, all safety regimen maintain to than for inhibition a evidence this, should still than be To timeline for decrease we clinical The XX% XX% and to formation days metabolized the typical preclinical minimal next-generation to and approved much provide the less presently and we metabolism minimizing if less better
Next slide.
line of FDA more to approach and individualized, are Given next-generation to de reactivated, with two, to Phase Capecitabine. DPD activity findings novo IRB better XXXX, formation. the was two working and we submitted possibility for trial. Xb a to inhibition Xb The And time restart protocol in treatment one, have patients. also, we’ve the we one the personalized are Phase begun February, Sites of DPD the the of modified adding and identify modified sites. dose modified being Sites an understand are approval using evaluate to after protocol single
second We expect XXXX. of to restart dosing patients quarter in the
end the on XXXX. preliminary DPD by results of overall determination of timeline of initiation MTD mid-XXXX, year. XXXX XXXX registration preliminary still by that The the the for pivotal next-generation submission in expect to an for a have trial and We the to timeline is and XXXX an NDA capcitabine
slide. Next
for review for lipoidica. we me treatment condition. Phase the a Let have which or PCSXXX, And no quickly care standard FDA of Xb necrobiosis orphan presently there even is of our designation treatment approved drug, for this
Next slide.
As XX,XXX in in ulcerative presents two NL. patients seen non-ulcerated lesion. contract these the painful or naturally ulcerated lipoidica pictures, with approximately to The or literature NL and from patients in U.S. NL, to necrobiosis NL the reports ulcers as occurring from as XX,XXX
billion the wound less, two healing to but note patients. this than in onset moderate-to-severe these numbers during incurs the of alter less It or first to after should potential X% However, is significantly closure ulcers complete years important $X of be natural the one not that may market.
called side as there off-label Next prevents used drugs as it ulcerative which metabolites, in high the of or PCSXXX NL no at that in dose see metabolite drugs to effects, are better be of inadequate no NL. in slide. analog qualitatively for or the the and ulcers a metabolites has has the does but care, a a is This given patients, I call limit limits drug PTX efficacy. includes because duterated treatment profile. standard same significant PCSXXX dose-limiting side often efficacy FDA-approved resulting PTX. is of all trial. a of can enough Currently, amounts of to There’s then PTX. the of but different work quantitatively the PTX, dose the safety closing be effects some which administered, a pentoxifylline
Next slide.
ulcers. wound the with achieved NL our addition, two trial, who only In was presented Phase complete closure Xa patients in in
Next slide.
these Xb we preliminary. patients randomized this So are what PCSXXX? receive time, overall. our patients the showing if with know have the some in improvement of placebo, closure XXXX for NL We’ve in and three complete these a do not only Phase trial, enrolled patients wound findings At in in accomplished blinded PCSXXX results we the placebo-controlled and lesion preliminary or
having don’t ulcerative years enrolling a the to of interested have the number patients COVID. than patients to because conditions of with other be and potentially combined ulcer to willing such travel ulcers patients travel risk, in had medical want little to a Many that have are even The these as exposed willing lived but not We NL sites. diabetes continue we rather in COVID travel. longer tolerating for
to after answered should results questions evaluating expected XXXX. who Complete study, X also of in In died fact, final interim enrollment fewer additional in and We enrolled of we year. this and sites we began obtain patients into Xb and patients on the the replacing is by remedial FDA the PCSXXX the trial analysis. not the last year. be U.S. with the group expected We’ve end end at were by if closed be response and COVID the the completed information in in December number of X/XX/XXXX, Since improve a analysis sites purpose Phase the the initiated can before interest at expressed we ex-U.S. of screening the efforts also that Phase enrollment, in a meet recruiting are well, To process. Europe is with couple plan possibly four placebo, of trial still a with the of end The sites of or from the to patients they is to study interim are actually new these have with interim these of the XXXX. trial came of the
next is The slide. Next PCSXXXXX. drug to discuss
Next slide.
can type shown the with of gastric Xa a patients. patients emptying effect on rate on Phase a effect our trial, symptoms me to the constipation. in which see Let in increases expect have have remind drug improvement been that to gastric already rate, in you the same significant gastroparesis. gastroparesis PCSXXXXX the of emptying we emptying significant In has the gastric
Next patients slide. that of for warning XX gastroparesis. black have FDA-approved only though the one a weeks, be and can drug At effects, only is even treatment the chronic present side there time, most for drug has serious box used And constipation.
Next slide.
activating clinical patient this the presently XXXX. for trial first are expect We sites second in be and to dosed our quarter of
final December or trial results enrollment complete and of XXXX in with We the expect XXXX begin the in top trial to Xb line to XXXX available January Phase XXXX.
two are are drugs drugs, cancer they slide. last and PCSXXXX Next The and PCSXXT.
of these Next development are and program to slides media slide. information these provide some please deck cancer remarks. The concludes both slides, and benefit both the population describe pipeline risk potential the questions? I efficacious The discuss who shown with but to have operator Operator, next milestones. three my lines next not potential drugs, drugs. Q&A. briefly summary billion; associated will the to they both the target the to a now open with status programs on ask for the the of been $X you of drug. the clinically of before drugs last for form. active in over the slides of these drugs can are each are slides for approval group treatments; phone three, two, been alternative the poll presently presented for and to be allows that A we one, each us of I’ll market defining in are background already road is, map cancer these need patients patients; lastly, drugs cancer these the in more This
